Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Atopic Hand and Foot Dermatitis
NCT06921759Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of lebrikizumab in atopic hand dermatitis, sponsored by Eli Lilly and Company. Started Apr 2025; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic hand dermatitis
Beyond the preview
Go deeper on NCT06921759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921759.